John Davis

John Davis:

John Davis is presently the Director of Investigative Toxicology at Pfizer MA, leading a group of scientists in Drug Safety Research and Development responsible for nonclinical toxicology screening and mechanistic studies; he has served as the toxicologist on numerous multidisciplinary project teams in both Research as well as Development; and he served on and led several clinical and nonclinical toxicology issue management teams.  Prior to joining Pfizer, John was a principal scientist in the Molecular Toxicology Group at Schering-Plough.  John received a BS in pharmacology and toxicology from the University of Wisconsin in 1990 and a Ph.D. in Molecular Toxicology from the Purdue University in 1998 (mentor Jack Vanden Heuvel).  He performed post-doctoral research on the regulation of kinase signaling and gene expression in normal human mammary epithelial cells at the University of New Mexico (mentor Scott Burchiel).  John has co-authored more than 20 peer-reviewed publications and reviews and has given numerous invited seminars at both scientific meetings as well as academic institutions.  He has also co-chaired multiple continuing education courses, symposia and workshops at both annual SOT and ACT meetings including the most recent SOT.  John is a founding/charter member of the Drug Discovery Toxicology Specialty Session, and has just completed the presidential track.  He has also participated in multiple industry-wide consortiums including the nephrotoxicity working group of the ILSI-HESI toxicogenomics group and the Critical Path Initiative’s nephrotixicity biomarkers working group.  John is an Adjunct Clinical Full Professor in the College of Pharmacy at the University of New Mexico.